DPP-4 억제제의 비교 |
김남훈, 김신곤 |
|
Comparison of DPP-4 Inhibitors. |
Nam Hoon Kim, Sin Gon Kim |
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr |
|
Abstract |
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them. |
Key Words:
Dipeptidyl-peptidase IV inhibitors, Incretins, Diabetes mellitus |
|